Interleukin-6 and disease activity in childhood systemic lupus erythematosus

  • Cahya Dewi Satria Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Central Java
  • Nia Kurniati Department of Child Health, Faculty of Medicine Universitas Indonesia, Jakarta
  • Dina Muktiarti Department of Child Health, Faculty of Medicine Universitas Indonesia, Jakarta
Keywords: Systemic Lupus Erythematosus, interleukin-6, disease activity, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)


Background Systemic lupus erythematosus (SLE) is a complex disease with various manifestations. Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biological activities which plays an important role in immune regulation and inflammation. Serum level of IL-6 may be used as a parameter of disease activity, especially in pediatric SLE patients with mild disease activity or total remission with conflicting clinical manifestations and Systemic  Lupus  Erythematosus  Disease  Activity Index (SLEDAI) scores.

Objective To identify the characteristics of serum IL-6 concentration in pediatric  SLE with mild disease activities and total remission.

Methods This case-control study was performed at the allergy-immunology outpatient clinic, Department of Child Health Dr. Cipto Mangunkusumo Hospital, Jakarta and Dr. Sardjito Hospital, Yogyakarta. Serum IL-6 concentration and disease activity were assessed in all pediatric SLE patients aged 1-18 years old. Disease activity was assessed with SLEDAI scores and serum level of IL-6 was measured by enzyme-linked immunosorbent assay.

Results Among 60 subjects included in this study, 30 subjects with mild activities were in the case group and 30 subjects with total remissions were in the control group. There was no difference in serum IL-6 concentration between the case and control group (OR 0.483; 95%CI 0.041to 5.628; P=0.500). In this study, 2 subjects with urinary tract infection had high serum IL-6 concentrations.

Conclusion There is no difference in serum IL-6 concentration between pediatric SLE patients with mild disease activities compared to total remissions.


1. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67:195 LP - 205. DOI:
2. Cavalcanti A, Santos R, Mesquita Z, Duarte ALBP, Lucena-Silva N. Cytokine profile in childhood-onset systemic lupus erythematosus: a cross-sectional and longitudinal study. Brazilian J Med Biol Res. 2017;5). DOI:
3. Manson JJ, Rahman A. Systemic lupus erythematosus. Orphanet J Rare Dis. 2006;1(1):6. DOI:
4. Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am. 2012;59(2):345-364. DOI:
5. Davis LS, Hutcheson J, Mohan C. The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interferon Cytokine Res. 2011;31:781-789. DOI:
6. Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2011;2011:432595. DOI:
7. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 2004;13:339-343. DOI:
8. Umare V, Nadkarni A, Nadkar M, et al. Do high-sensitivity C-reactive protein and serum interleukin-6 levels correlate with disease activity in systemic lupus erythematosus patients? J Postgrad Med. 2017;63:92-95. DOI:
9. Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Cytokines and systemic lupus erythematosus. Ann Rheum Dis. 2000;59(4):243-251.
10. Weiss JE. Pediatric systemic lupus erythematosus: more than a positive antinuclear antibody. Pediatr Rev. 2012;33:62-73; quiz 74. DOI:
11. Aberle T, Bourn RL, Chen H, et al. Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus. Lupus Sci Med. 2017;4:e000176. DOI:
12. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39:257-268. DOI:
13. Rahman A, Isenberg DA. Systemic Lupus Erythematosus. N Engl J Med. 2008;358:929-939. DOI:
14. Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2008;26:436—441.
15. Silva CAA, Leal MM, Leone C, et al. Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus. 2002;11:419-425. DOI:
16. dos Santos F de MM, Borges MC, Correia MITD, Telles RW, Lanna CCD. Assessment of nutritional status and physical activity in systemic lupus erythematosus patients. Rev Bras Reumatol. 2010;50:631-638.
17. Abdel Galil SM, Ezzeldin N, El-Boshy ME. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine. 2015;76:280-287. DOI:
18. Liu C-C, Kao AH, Manzi S, Ahearn JM. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis. 2013;5:210-233. DOI:
19. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295-a016295. DOI:
20. Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca M V. The role of interleukin 6 during viral infections. Front Microbiol. 2019;10:1057.
How to Cite
Satria C, Kurniati N, Muktiarti D. Interleukin-6 and disease activity in childhood systemic lupus erythematosus. PI [Internet]. 20Nov.2023 [cited 14Jun.2024];63(6):456-3. Available from:
Pediatric Allergy Immunology
Received 2022-06-05
Accepted 2023-11-20
Published 2023-11-20